::: 큐라티스 :::

SITE MAP

Quratis

Tel : +82 2 866 0604 Fax : +82 2 867 0125 Email : info@quratis.com

Tuberculosis (TB), a disease caused by bacteria called Mycobacterium tuberculosis, is one of the world’s deadliest communicable diseases. TB is spread from person to person through the air when a person with TB of the lungs or throat coughs, sneezes, or talks. Approximately 9.87 million people develop TB and 1.49 million die from the disease each year. Thanks to the discovery of antibiotics, TB has become a curable disease. However, TB remains one of the most serious infectious complications among immunocompromised patients, such as AIDS patients, transplantation patients, patients with TNF antagonist treatment. The emergence and outbreak of multidrug resistant strains also become a major challenge to treat this disease. In particular, Korea has one of the highest TB incidence rates among the OECD countries.

Bacille Calmette-Guerin (BCG) vaccine is the only existing tuberculosis vaccine, but it is known to be ineffective in adolescents and adults. There is a need to develop a new vaccine because the duration of CG efficacy is about 10 years after inoculation in neonates, and the protective efficacy of BCG does not improve even after re-vaccination.
One of the most effective strategies for developing a tuberculosis vaccine is the Prime-Boost Immunization Strategy, which provides secondary vaccines to adolescents or adults who have been previously BCG vaccinated in childhood to enhanced projection against tuberculosis

QTP101 is a multiple-antigen protein fusion vaccine composed of three virulent antigens (Rv3619, Rv3620, Rv2608) and one latency-associated antigen (Rv1813) with GLA-SE (TLR4 agonist) adjuvant. This subunit vaccine shows enhanced safety and increased productivity through our manufacturing process development.

The efficacy of QTP101 as a BCG booster vaccine was verified in animal models. In addition, QTP101 has no cross-reactivity with the PPD skin test and the IGRA test, excluding the possibility of a false-positive reaction with these tests after the QTP101 vaccination.

Partners